Drugs / RO7496998
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04889040 | Apr → Dec 2021 | COVID-19 | Hoffmann-La Roche | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7496998 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04889040 ↗ |
| Modality | Small molecule | “a novel, oral nucleotide analog” PMID 37928891 ↗ Nov 2023 |
| Route | Oral | “Orally administered, 550 mg twice daily (BID) for 5 days” NCT04889040 ↗ |